아토피피부염 환자에서 국소 tacrolimus 0.1%에 대한 약물정보지 제공의 효과 및 국소 tacrolimus 0.1% 효능과 환자의 순응도 평가
Effect of infosheet for topical tacrolimus 0.1% and its efficacy and compliance in the treatment of atopic dermatitis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. Methods: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient’s global assessment (PGA), and investigator’s global assessment (IGA). Results: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. Conclusion: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance.
Abstract
Purpose: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. Methods: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient’s global assessment (PGA), and investigator’s global assessment (IGA). Results: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. Conclusion: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance.
참고문헌 (22)
- Kabashima K, "New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity", J Dermatol Sci, 70, pp.3~11 (2013)
- Guin JD, "Complications of topical hydrocortisone", J Am Acad Dermatol, 4, pp.417~422 (1981)
- Graham-Brown R, "Managing adults with atopic dermatitis", Dermatol Clin, 14, pp.531~537 (1996)
- Chase EP, "Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments", Semin Cutan Med Surg, 31, pp.17~24 (2012)
- Nasr IS, "Topical tacrolimus in dermatology", Clin Exp Dermatol, 25, pp.250~254 (2000)
- Gupta AK, "Tacrolimus: a review of its use for the management of dermatoses", J Eur Acad Dermatol Venereol, 16, pp.100~114 (2002)
- Katoh N, "Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis", J Dermatol, 31, pp.194~199 (2004)
- Hanifin JM, "Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy", J Am Acad Dermatol, 44(1 Suppl), pp.S28~38 (2001)
- Soter NA, "Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety", J Am Acad Dermatol, 44(1 Suppl), pp.S39~46 (2001)
- Kapp A, "Atopic dermatitis management with tacrolimus ointment (Protopic)", J Dermatolog Treat, 14, pp.5~16 (2003)
- Ruzicka T, "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group", N Engl J Med, 337, pp.816~821 (1997)
- Won CH, "A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea", J Dermatolog Treat, 15, pp.30~34 (2004)
- Choi WW, "Tacrolimus ointment; an open study for effects on severe facial atopic dermatitis in Korean", Ann Dermatol, 14, pp.195~199 (2002)
- 김혜원, "한국인 아토피 피부염 환자에서 0.1% tacrolimus 연고의 치료 효과", 대한피부과학회지, 43(3), pp.312~318 (2005), 대한피부과학회
- Luoma R, "Development of asthma, allergic rhinitis and atopic dermatitis by the age of five years: a prospective study of 543 newborns", Allergy, 38, pp.339~346 (1983)
- Park YM, "The study on the hospital - based relative frequency, and clinical and laboratory findings of atopic dermatitis", Korean J Dermatol, 35, pp.96~106 (1997)
- Hanifin JM, "Diagnostic features of atopic dermatitis", Acta Derm Venereol Suppl, (Suppl 92), pp.44~47 (1980)
- Williams HC, "On the definition and epidemiology of atopic dermatitis", Dermatol Clin, 13, pp.649~657 (1995)
- Lee HJ, "Minor cutaneous features of atopic dermatitis in South Korea", Int J Dermatol, 39, pp.337~342 (2000)
- 김범준, "아토피피부염 환자에서 국소 피메크로리무스의 효과와 순응도에 관한 다기관 설문조사", 대한피부과학회지, 46(10), pp.1357~1361 (2008), 대한피부과학회
- Simpson EL, "Atopic dermatitis", J Am Acad Dermatol, 53, pp.115~128 (2005)
- Rustin MH, "The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review", Br J Dermatol, 157, pp.861~873 (2007)